Stockreport

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Cognition Therapeutics, Inc.  (CGTX) 
PDF Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervime [Read more]